Contract Awards

Not specified

Direct Adjustment For B770- Bevacizumab [25 Mg/Ml; 100 Mg/ 4 Ml; Conc To Sol For Perfusion; Frs] Patients Under Treatment, B771- Bevacizumab [25 Mg/Ml; 400 Mg/ 16 Ml; Conc To Sol For Perfusion; Frs] Patients Undergoing Treatment, R148- Rituximab [500 Mg/ 50 Ml; Frs] Patients Undergoing Treatment, T1266- Tocilizumab [162 Mg/0.9 Ml; Sol Inj; Syringe], T1592- Tocilizumab [162 Mg/ 0.9 Ml; Pen], T1132- Tocilizumab [20 Mg/Ml; 10 Ml; Frs], T1133- Tocilizumab [20 Mg/Ml; 20 Ml; Frs] And T1134- Tocilizuma